Salivary Gland Carcinoma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AT
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Actuate Therapeutics9-ING-41
Merck & Co.Goserelin Acetate
Clinical Trials (2)
Total enrollment: 20 patients across 2 trials
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Start: Dec 2030Est. completion: Jun 2034
Phase 2Withdrawn
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Start: May 2019Est. completion: Aug 202620 patients
Phase 2Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
2h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
2h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
2h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 20 patients
2 companies competing in this space